MRTX - Amgen Mirati's Lumakras can target 13% of the NSCLC market

Amgen (AMGN) and Mirati Therapeutics' (MRTX) just approved KRAS inhibitor Lumakras (sotorasib) for non-small cell lung cancer ("NSCLC") could be used with as many as 13% of those patients.Lumakras is specifically approved for NSCLC patients with the KRAS G12C generic mutation who have failed one prior therapy, and statistics show 13% of NSCLC patients have this mutation.Data from the American Cancer Society indicates that an estimated 235,760 new cases of lung cancer -- both non-small and small -- will be diagnosed this year in the U.S. Worldwide, 2.1M people are diagnosed annually. About 84% of lung cancer diagnoses are NSCLC.Current second-line treatments for NSCLC include Eli Lilly's (LLY) Cyramza (ramucirumab), Bristol-Myers Squibb's (BMY) Opdivo (nivolumab), Merck's (MRK) Keytruda (pembrolizumab), Boehringer Ingelheim's Gilotrif (afatinib), and Roche's (RHHBY) Tarceva (erlotinib).Amgen shares are up 1.3% to $238.44 and Mirati shares are up 3.2% to $157.87 in afternoon trading.

For further details see:

Amgen, Mirati's Lumakras can target 13% of the NSCLC market